Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes

Junichiro Irie, Yuehong Wu, Kritika Kachapati, Robert S. Mittler, William M. Ridgway

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

CD137 (TNFRSF9) is an activation-inducible T-cell costimulatory molecule and a member of the tumor necrosis factor (TNF) receptor superfamily. Cd137 is also a candidate gene (in the Idd9.3 interval) for autoimmune diabetes in NOD mice. Here, we demonstrate that anti-CD137 treatment protects NOD mice from diabetes. Anti-CD137-treated mice are not protected from insulitis and still harbor pathogenic T-cells, as demonstrated by transfer studies. Transfer of CD4+, but not CD8+, cells from anti-CD137-treated pre-diabetic NOD mice into NOD-scid mice delayed diabetes onset. Anti-CD137 treatment significantly increased the number of CD4+CD25+ cells, which demonstrated intracellular Foxp3 expression and in vitro suppressive activity. The CD4+CD25+ cell subset from anti-CD137-treated mice transferred complete protection from diabetes, whereas the CD4+CD25- cell subset offered no significant protection. Anti-CD137 treatment of NODscid recipients of diabetic spleen cells, however, hastened the onset of disease, showing that the effect of anti-CD137 treatment depends on the balance of pathogenic and protective cells. These results support a critical role for CD137 acting in the early phase of autoimmune diabetes to enhance regulatory cell production. Disease-associated CD137 alleles are likely ineffectual at stimulating a regulatory T-cell population sufficient to prevent disease.

Original languageEnglish
Pages (from-to)186-196
Number of pages11
JournalDiabetes
Volume56
Issue number1
DOIs
Publication statusPublished - 2007 Jan
Externally publishedYes

Fingerprint

Type 1 Diabetes Mellitus
Inbred NOD Mouse
T-Lymphocytes
Tumor Necrosis Factor Receptors
Regulatory T-Lymphocytes
Spleen
Alleles
Population
Genes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Irie, J., Wu, Y., Kachapati, K., Mittler, R. S., & Ridgway, W. M. (2007). Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. Diabetes, 56(1), 186-196. https://doi.org/10.2337/db06-0793

Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. / Irie, Junichiro; Wu, Yuehong; Kachapati, Kritika; Mittler, Robert S.; Ridgway, William M.

In: Diabetes, Vol. 56, No. 1, 01.2007, p. 186-196.

Research output: Contribution to journalArticle

Irie, J, Wu, Y, Kachapati, K, Mittler, RS & Ridgway, WM 2007, 'Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes', Diabetes, vol. 56, no. 1, pp. 186-196. https://doi.org/10.2337/db06-0793
Irie, Junichiro ; Wu, Yuehong ; Kachapati, Kritika ; Mittler, Robert S. ; Ridgway, William M. / Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes. In: Diabetes. 2007 ; Vol. 56, No. 1. pp. 186-196.
@article{0cf683b6753c4e2bb2d857ac8c118110,
title = "Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes",
abstract = "CD137 (TNFRSF9) is an activation-inducible T-cell costimulatory molecule and a member of the tumor necrosis factor (TNF) receptor superfamily. Cd137 is also a candidate gene (in the Idd9.3 interval) for autoimmune diabetes in NOD mice. Here, we demonstrate that anti-CD137 treatment protects NOD mice from diabetes. Anti-CD137-treated mice are not protected from insulitis and still harbor pathogenic T-cells, as demonstrated by transfer studies. Transfer of CD4+, but not CD8+, cells from anti-CD137-treated pre-diabetic NOD mice into NOD-scid mice delayed diabetes onset. Anti-CD137 treatment significantly increased the number of CD4+CD25+ cells, which demonstrated intracellular Foxp3 expression and in vitro suppressive activity. The CD4+CD25+ cell subset from anti-CD137-treated mice transferred complete protection from diabetes, whereas the CD4+CD25- cell subset offered no significant protection. Anti-CD137 treatment of NODscid recipients of diabetic spleen cells, however, hastened the onset of disease, showing that the effect of anti-CD137 treatment depends on the balance of pathogenic and protective cells. These results support a critical role for CD137 acting in the early phase of autoimmune diabetes to enhance regulatory cell production. Disease-associated CD137 alleles are likely ineffectual at stimulating a regulatory T-cell population sufficient to prevent disease.",
author = "Junichiro Irie and Yuehong Wu and Kritika Kachapati and Mittler, {Robert S.} and Ridgway, {William M.}",
year = "2007",
month = "1",
doi = "10.2337/db06-0793",
language = "English",
volume = "56",
pages = "186--196",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "1",

}

TY - JOUR

T1 - Modulating protective and pathogenic CD4+ subsets via CD137 in type 1 diabetes

AU - Irie, Junichiro

AU - Wu, Yuehong

AU - Kachapati, Kritika

AU - Mittler, Robert S.

AU - Ridgway, William M.

PY - 2007/1

Y1 - 2007/1

N2 - CD137 (TNFRSF9) is an activation-inducible T-cell costimulatory molecule and a member of the tumor necrosis factor (TNF) receptor superfamily. Cd137 is also a candidate gene (in the Idd9.3 interval) for autoimmune diabetes in NOD mice. Here, we demonstrate that anti-CD137 treatment protects NOD mice from diabetes. Anti-CD137-treated mice are not protected from insulitis and still harbor pathogenic T-cells, as demonstrated by transfer studies. Transfer of CD4+, but not CD8+, cells from anti-CD137-treated pre-diabetic NOD mice into NOD-scid mice delayed diabetes onset. Anti-CD137 treatment significantly increased the number of CD4+CD25+ cells, which demonstrated intracellular Foxp3 expression and in vitro suppressive activity. The CD4+CD25+ cell subset from anti-CD137-treated mice transferred complete protection from diabetes, whereas the CD4+CD25- cell subset offered no significant protection. Anti-CD137 treatment of NODscid recipients of diabetic spleen cells, however, hastened the onset of disease, showing that the effect of anti-CD137 treatment depends on the balance of pathogenic and protective cells. These results support a critical role for CD137 acting in the early phase of autoimmune diabetes to enhance regulatory cell production. Disease-associated CD137 alleles are likely ineffectual at stimulating a regulatory T-cell population sufficient to prevent disease.

AB - CD137 (TNFRSF9) is an activation-inducible T-cell costimulatory molecule and a member of the tumor necrosis factor (TNF) receptor superfamily. Cd137 is also a candidate gene (in the Idd9.3 interval) for autoimmune diabetes in NOD mice. Here, we demonstrate that anti-CD137 treatment protects NOD mice from diabetes. Anti-CD137-treated mice are not protected from insulitis and still harbor pathogenic T-cells, as demonstrated by transfer studies. Transfer of CD4+, but not CD8+, cells from anti-CD137-treated pre-diabetic NOD mice into NOD-scid mice delayed diabetes onset. Anti-CD137 treatment significantly increased the number of CD4+CD25+ cells, which demonstrated intracellular Foxp3 expression and in vitro suppressive activity. The CD4+CD25+ cell subset from anti-CD137-treated mice transferred complete protection from diabetes, whereas the CD4+CD25- cell subset offered no significant protection. Anti-CD137 treatment of NODscid recipients of diabetic spleen cells, however, hastened the onset of disease, showing that the effect of anti-CD137 treatment depends on the balance of pathogenic and protective cells. These results support a critical role for CD137 acting in the early phase of autoimmune diabetes to enhance regulatory cell production. Disease-associated CD137 alleles are likely ineffectual at stimulating a regulatory T-cell population sufficient to prevent disease.

UR - http://www.scopus.com/inward/record.url?scp=33847042307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847042307&partnerID=8YFLogxK

U2 - 10.2337/db06-0793

DO - 10.2337/db06-0793

M3 - Article

C2 - 17192481

AN - SCOPUS:33847042307

VL - 56

SP - 186

EP - 196

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 1

ER -